Synlett 2005(7): 1191-1194  
DOI: 10.1055/s-2005-865218
LETTER
© Georg Thieme Verlag Stuttgart · New York

Solid-Supported Sulfonylhydroxylamine as an Effective N-Aminating Agent of Anilines

Hiroshi Ohno*a, Hiroshi Tanakab, Takashi Takahashi*b
a Department of Medicinal Chemistry, Pharmaceutical Research Laboratory, Toray Industries, Inc., 1111 Tebiro, Kamakura, Kanagawa 248-8555, Japan
Fax: +81(467)324791; e-Mail: Hiroshi_Ono@nts.toray.co.jp;
b Department of Applied Chemistry, Tokyo Institute of Technology, Meguro, Tokyo 152-8552, Japan
Weitere Informationen

Publikationsverlauf

Received 16 November 2004
Publikationsdatum:
20. April 2005 (online)

Abstract

An effective method for the synthesis of aryl hydrazines by amination of anilines using the solid-supported phenylsulfonylhydroxylamine was described. Treatment of aniline with the solid-supported aminating agent, followed by removal of the resin, provided the corresponding hydrazine in 21% yield. The resulting hydrazines were directly adapted to the solid-phase synthesis of indoles, providing nine naltrindole derivatives varying the substituents on the aromatic rings.

12

Procedure for the Preparation of 7.
To a mixture of PS-TsCl (Argonout, 1.97 mmol/g, 2.0 g, 3.9 mmol) and N-Boc-hydroxylamine (1.05 g, 7.9 mmol) in THF (32 mL) was added THF solution (4 mL) of Et3N (1.1 mL, 7.9 mmol) slowly at 0 °C. The mixture was shaken for 1.5 h at r.t. After filtration of the mixture, the resulting resin was washed with THF, H2O, and THF, and dried in vacuo to give resin-supported N-Boc sulfonyl hydroxylamine 7 (2.6 g). IR (resin): 1475, 1396, 1173 cm-1. Anal. Found: C, 68.78; H, 7.40; N, 2.22; Cl, 0.02; S, 5.52%.

13

The ratio was estimated by 1H NMR measurement of the crude mixture.

14

Typical Experimental Procedure.
To resin-supported N-Boc sulfonyl hydroxylamine (7, 100 mg), TFA (1 mL, pre-cooled at 0 °C) was added at r.t., and the mixture was shaken for 1 min at r.t. After filtration of the mixture, the resulting resin was washed with H2O, THF, and CH2Cl2 (pre-cooled at 0 °C) to give the polystyrene-supported sulfonyl hydroxylamine 1B. The resulting resin was used for next amination without drying. To the resulting resin 1B was added aniline (27 µL, 0.29 mmol) in CH2Cl2 (0.5 mL, pre-cooled at 0 °C), and the mixture was shaken for 10 min at r.t. After filtration of the mixture followed by washing with CH2Cl2, the resulting resin were treated with CH2Cl2-HCl (10 M) in MeOH (1:1), filtered, and then washed with CH2Cl2-HCl (10 M) in MeOH (1:1). The combined filtrates were evaporated, and dried in vacuo to give of crude phenylhydrazine HCl (17.1 mg). Further purification was achieved by silica gel column chromatography followed by adding 10 M HCl in MeOH to give phenylhydrazine HCl (4.0 mg, 28 µmol).

17

The lower yield than previously reported [16a] was due to the different ways of estimation of the yield. The yield was determined by measurement of mass weight of cleavage product in the former paper, on the other hand in this paper the yield is isolated yield.

18

Spectra of 8d: 1H NMR (400 MHz, CD3OD): δ = 0.13-0.23 (2 H, m), 0.52-0.61 (2 H, m), 0.93 (1 H, m), 1.30 (3 H, t, J = 7.6 Hz), 1.72 (1 H, d, J = 12.2 Hz), 2.28-2.50 (4 H, m), 2.56 (1 H, d, J = 15.9 Hz), 2.73 (1 H, d, J = 15.9 Hz), 2.73-2.90 (4 H, m), 3.17 (1 H, d, J = 18.6 Hz), 3.40 (1 H, d, J = 6.3 Hz), 5.59 (1 H, s), 6.53 (1 H, d, J = 8.1 Hz), 6.56 (1 H, d, J = 8.1 Hz), 7.00 (1 H, d, J = 1.7 Hz), 7.34 (1 H, d, J = 1.7 Hz). 13C NMR (150.8 MHz, CD3OD): δ = 4.2, 4.8, 10.3, 14.6, 24.1, 25.1, 29.8, 32.8, 45.0, 60.4, 63.4, 74.4, 85.7, 111.1, 113.0, 118.2, 119.6, 119.7, 124.4, 126.0, 129.3, 130.2, 131.8, 131.9, 135.8, 140.8, 144.5. MS (ESI): 521 [M + H]+.
Spectra of 8e: 1H NMR (400 MHz, CD3OD): δ = 0.13-0.22 (2 H, m), 0.51-0.60 (2 H, m), 0.93 (1 H, m), 1.73 (1 H, d, J = 12.5 Hz), 2.28-2.47 (4 H, m), 2.49 (3 H, s), 2.57 (1 H, d, J = 15.9 Hz), 2.68-2.85 (2 H, m), 2.76 (1 H, d, J = 15.9 Hz), 3.17 (1 H, d, J = 18.6 Hz), 3.40 (1 H, d, J = 6.3 Hz), 5.59 (1 H, s), 6.52 (1 H, d, J = 8.1 Hz), 6.55 (1 H, d, J = 8.1 Hz), 6.90 (1 H, d, J = 8.4 Hz), 7.16 (1 H, d, J = 8.4 Hz). 13C NMR (150.8 MHz, CD3OD): δ = 4.2, 4.8, 10.3, 14.1, 24.1, 29.8, 32.7, 45.0, 60.4, 63.5, 74.4, 85.8, 111.8, 117.8, 118.2, 119.3, 119.6, 120.9, 125.9, 126.2, 128.4, 131.5, 131.9, 138.5, 140.8, 144.5. MS (ESI): 463 [M + H]+.
Spectra of 8f: 1H NMR (400 MHz, CD3OD): δ = 0.15-0.24 (2 H, m), 0.52-0.62 (2 H, m), 0.95 (1 H, m), 1.26-1.42 (18 H, m), 1.74 (1 H, m), 2.35-2.49 (4 H, m), 2.71-2.81 (3 H, m), 3.18-3.26 (2 H, m), 3.36 (1 H, d, J = 6.3 Hz), 5.61 (1 H, s), 6.53 (1 H, d, J = 8.2 Hz), 6.56 (1 H, d, J = 8.2 Hz), 7.05 (1 H, d, J = 1.7 Hz), 7.20 (1 H, d, J = 1.7 Hz). 13C NMR (150.8 MHz, CD3OD): δ = 4.3, 4.7, 10.3, 24.2, 31.9, 32.2, 33.0, 35.6, 36.3, 36.5, 44.9, 48.0, 60.5, 63.9, 75.0, 86.6, 107.0, 108.9, 115.2, 118.2, 119.5, 122.6, 125.9, 130.9, 132.1, 140.1, 140.8, 144.3, 144.8, 145.1. MS (ESI): 527 [M + H]+.
Spectra of 8g: 1H NMR (400 MHz, CD3OD): δ = 0.15-0.24 (2 H, m), 0.52-0.61 (2 H, m), 0.94 (1 H, m), 1.73 (1 H, m), 1.81-1.91 (4 H, m), 2.31-2.49 (4 H, m), 2.59 (1 H, d, J = 15.9 Hz), 2.75-2.87 (7 H, m), 3.17 (1 H, d, J = 18.6 Hz), 3.41 (1 H, d, J = 5.9 Hz), 5.60 (1 H, s), 6.52 (1 H, d, J = 8.2 Hz), 6.54 (1 H, d, J = 8.2 Hz), 6.67 (1 H, d, J = 8.1 Hz), 7.10 (1 H, d, J = 8.1 Hz). 13C NMR (150.8 MHz, CD3OD): δ = 4.2, 4.8, 10.2, 24.2, 24.2, 24.9, 25.4, 30.0, 30.6, 32.7, 45.0, 49.9, 60.4, 63.5, 74.4, 86.3, 116.7, 118.1, 119.4, 120.4, 121.5, 125.3, 125.9, 129.5, 131.3, 132.1, 137.7, 140.8, 144.5, 150.4. MS (ESI): 469 [M + H]+.
Spectra of 8h: 1H NMR (400 MHz, CD3OD): δ = 0.12-0.22 (2 H, m), 0.49-0.60 (2 H, m), 0.92 (1 H, m), 1.75 (1 H, d, J = 12.7 Hz), 2.27-2.46 (4 H, m), 2.66 (1 H, d, J = 15.6 Hz), 2.71-2.76 (1 H, m), 2.83 (1 H, d, J = 18.6 Hz), 2.84 (1 H, d, J = 15.9 Hz), 3.17 (1 H, d, J = 18.6 Hz), 3.42 (1 H, d, J = 6.3 Hz), 5.68 (1 H, s), 6.54 (1 H, d, J = 8.2 Hz), 6.57 (1 H, d, J = 8.2 Hz), 7.45-7.49 (1 H, m), 7.51-7.55 (1 H, m), 7.58 (1 H, s), 8.19-8.23 (2 H, m). 13C NMR (150.8 MHz, CD3OD): δ = 4.2, 4.7, 10.2, 24.1, 29.7, 32.7, 44.8, 60.3, 63.3, 74.4, 85.7, 112.6, 118.0, 119.5, 119.7, 121.7, 122.8, 123.5, 123.9, 125.3, 125.8, 125.9, 126.8, 128.2, 129.9, 131.7, 132.3, 140.6, 144.4. MS (ESI): 499 [M + H]+.
Spectra of 8i: 1H NMR (400 MHz, CD3OD): δ = 0.12-0.24 (2 H, m), 0.51-0.62 (2 H, m), 0.87-0.97 (1 H, m), 1.73-1.76 (1 H, m), 2.28-2.50 (4 H, m), 2.63 (1 H, d, J = 14.6 Hz), 2.72-2.88 (2 H, m), 2.81 (1 H, d, J = 15.6 Hz), 3.18 (1 H, d, J = 18.6 Hz), 3.42 (1 H, d, J = 6.6 Hz), 3.81 (1 H, d, J = 22.0 Hz), 3.90 (1 H, d, J = 21.7 Hz), 5.63 (1 H, s), 6.54 (1 H, d, J = 8.1 Hz), 6.56 (1 H, d, J = 8.1 Hz), 7.15-7.19 (1 H, m), 7.26-7.30 (1 H, m), 7.31 (1 H, d, J = 8.1 Hz), 7.41 (1 H, d, J = 8.3 Hz), 7.46 (1 H, d, J = 7.3 Hz), 7.68 (1 H, d, J = 7.6 Hz). 13C NMR (150.8 MHz, CD3OD): δ = 4.2, 4.8, 10.3, 24.2, 30.1, 32.7, 35.2, 45.0, 60.4, 63.5, 74.4, 86.1, 112.2, 112.4, 118.2, 118.5, 119.6, 119.8, 125.6, 126.0, 126.1, 126.5, 127.4, 127.6, 131.0, 132.1, 135.5, 137.8, 140.9, 143.5, 144.4, 144.6. MS (ESI): 503 [M + H]+.